NCT02588651 2025-11-21A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)Case Comprehensive Cancer CenterPhase 2 Completed23 enrolled 15 charts
NCT03113500 2025-11-14Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaCity of Hope Medical CenterPhase 2 Active not recruiting48 enrolled 8 charts
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts